Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer

被引：0
|
作者：
Adesoye, Taiwo
Luo, Linjie
Bui, Tuyen
Kim, Serena
Wingate, Hannah
Tripathy, Debu
Hunt, Kelly
Keyomarsi, Khandan
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-25-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-25-08
引用
收藏
页数：3
相关论文
共 50 条
  • [41] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Neil Portman
    Heloisa H. Milioli
    Sarah Alexandrou
    Rhiannon Coulson
    Aliza Yong
    Kristine J. Fernandez
    Kee Ming Chia
    Ensar Halilovic
    Davendra Segara
    Andrew Parker
    Sue Haupt
    Ygal Haupt
    Wayne D. Tilley
    Alex Swarbrick
    C. Elizabeth Caldon
    Elgene Lim
    Breast Cancer Research, 22
  • [42] Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
    Wang, Qingfei
    Guldner, Ian H.
    Golomb, Samantha M.
    Sun, Longhua
    Harris, Jack A.
    Lu, Xin
    Zhang, Siyuan
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [43] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [44] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Lim, Elgene
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, KeeMing
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, Elizabeth C.
    Portman, Neil
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 110 - 110
  • [45] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
    Portman, Neil
    Milioli, Heloisa H.
    Alexandrou, Sarah
    Coulson, Rhiannon
    Yong, Aliza
    Fernandez, Kristine J.
    Chia, Kee Ming
    Halilovic, Ensar
    Segara, Davendra
    Parker, Andrew
    Haupt, Sue
    Haupt, Ygal
    Tilley, Wayne D.
    Swarbrick, Alex
    Caldon, C. Elizabeth
    Lim, Elgene
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [46] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
    Kanthala, Shanthi
    Banappagari, Sashikanth
    Gokhale, Ameya
    Liu, Yong-Yu
    Xin, Gu
    Zhao, Yunfeng
    Jois, Seetharama
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
  • [47] Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
    Guarducci, C.
    Nardone, A.
    Feiglin, A.
    Migliaccio, I.
    Malorni, L.
    Bonechi, M.
    Benelli, M.
    Di Leo, A.
    Hodgson, G.
    Shapiro, G.
    Brown, M.
    Jeselsohn, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, Kenji
    Macaulay, Valentine
    Kong, Anthony
    CANCER RESEARCH, 2014, 74 (19)
  • [49] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [50] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
12345